Welcome to our dedicated page for Kronos Bio SEC filings (Ticker: KRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Kronos Bio’s SEC disclosures can feel like decoding a lab notebook. Because the company engineers small-molecule inhibitors that modulate deregulated transcription, its filings weave together pre-clinical pharmacology, phase-1 trial protocols, share-based milestone payments, and layered risk factors. Investors often ask, “What does Kronos Bio report in its 10-K?” or search for “Kronos Bio SEC filings explained simply.” If locating insider data or clinical spend inside a 300-page document slows your research, you’re not alone.
Stock Titan’s AI changes that experience. Our engine highlights the passages that matter—cash runway, CDK9 trial timelines, manufacturing commitments—then delivers plain-English summaries you can read in minutes. Real-time alerts ensure you never miss the Kronos Bio Form 4 insider transactions real-time feed or a fresh 8-K describing material trial results. The platform layers expert context so you’re not just reading numbers; you’re understanding Kronos Bio SEC documents with AI support.
From the Kronos Bio quarterly earnings report 10-Q filing to the Kronos Bio annual report 10-K simplified, every form lives here alongside AI commentary and downloadable spreadsheets. Track Kronos Bio insider trading Form 4 transactions, monitor executive stock transactions Form 4 before financing rounds, and review Kronos Bio earnings report filing analysis within minutes of release. Need governance details? The Kronos Bio proxy statement executive compensation file is indexed line-by-line. When unexpected news breaks, the Kronos Bio 8-K material events explained section shows what moved the stock and why. One page, every disclosure, zero wasted time.
Key event: Form 4 discloses that director David M. Tanen has disposed of 100 % of his equity position in Kronos Bio (KRON) on 20 June 2025.
The disposition covers 887,408 common shares (363,428 held directly and 523,980 held through a revocable trust and family members) at the previously announced tender-offer cash price of $0.57 per share plus one non-transferable contingent value right (CVR) per share. All positions are now reported as zero.
Simultaneously, 227,100 stock options with exercise prices ranging from $0.95 to $24.18 were cancelled pursuant to the merger terms. Options with strike prices below $0.57 became fully vested and entitled the holder to a cash-out equal to the intrinsic value (cash amount minus exercise price) plus one CVR per underlying share; options that were at or above $0.57 received no consideration.
The transactions were executed in accordance with the Agreement and Plan of Merger dated 1 May 2025 among Kronos Bio, Concentra Biosciences, and Merger Sub IV. Concentra completed the tender offer on 18 June 2025 and immediately merged with Kronos Bio, which now operates as a wholly owned subsidiary of Concentra. At the effective time, all outstanding Kronos Bio shares (other than excluded shares) were cancelled and converted into the right to receive the offer price.
Following these actions, Mr. Tanen is no longer a beneficial owner of Kronos Bio securities, and Section 16 insider reporting obligations for this issuer will cease unless he acquires new positions.
Form 4 filing overview for Kronos Bio, Inc. (KRON)
The filing details the disposition of four tranches of stock options held by director Roshawn A. Blunt on 20 June 2025. The options, with exercise prices of $17.10, $3.53, $1.48 and $0.95, were cancelled or exchanged in connection with the closing of Kronos Bio’s merger with Concentra Biosciences LLC.
- Merger consideration for common shareholders: $0.57 per share in cash plus one contingent value right (CVR).
- Pursuant to the merger agreement, all unexercised options became fully vested immediately prior to the effective time.
- If an option’s exercise price was higher than the $0.57 cash amount, it was cancelled for no consideration; otherwise, the holder received the cash spread plus one CVR per underlying share.
- All four option grants had exercise prices above $0.57, resulting in no economic value to the reporting person. Post-transaction, Blunt reports zero derivative securities beneficially owned.
- The tender offer and subsequent merger were completed on 18 June 2025; the Form 4 documents changes dated 20 June 2025.
Because the merger converts Kronos Bio into a wholly-owned subsidiary of Concentra, this filing also serves as notice that the director is no longer subject to Section 16 reporting.
FAQ
What is the current stock price of Kronos Bio (KRON)?
What is the market cap of Kronos Bio (KRON)?
What is the primary focus of Kronos Bio, Inc.?
How does Kronos Bio's proprietary discovery engine work?
What therapeutic areas does the company target?
What differentiates Kronos Bio in a competitive market?
What are the key technologies used by Kronos Bio?
How does the company approach its therapeutic pipeline?
How is Kronos Bio positioned in the field of oncology?
What challenges does Kronos Bio face in drug development?
